Department of Bioscience and Biotechnology, Konkuk University, Seoul 05029, Korea.
Palestine-Korea Biotechnology Center, Palestine Polytechnic University, Hebron 90100, Palestine.
Viruses. 2021 Apr 28;13(5):787. doi: 10.3390/v13050787.
One of the most effective strategies for eliminating new and emerging infectious diseases is effective immunization. The pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) warrants the need for a maximum coverage vaccine. Moreover, mutations that arise within the virus have a significant impact on the vaccination strategy. Here, we built a comprehensive workflow pipeline to identify B-cell- and T-cell-stimulating antigens of SARS-CoV-2 viral proteins. Our reverse vaccinology (RV) approach consisted of two parts: (1) analysis of the selected viral proteins based on annotated cellular location, antigenicity, allele coverage, epitope density, and mutation density and (2) analysis of the various aspects of the epitopes, including antigenicity, allele coverage, IFN-γ induction, toxicity, host homology, and site mutational density. After performing a mutation analysis based on the contemporary mutational amino acid substitutions observed in the viral variants, 13 potential epitopes were selected as subunit vaccine candidates. Despite mutational amino acid substitutions, most epitope sequences were predicted to retain immunogenicity without toxicity and host homology. Our RV approach using an pipeline may potentially reduce the time required for effective vaccine development and can be applicable for vaccine development for other pathogenic diseases as well.
消除新发传染病的最有效策略之一是进行有效的免疫接种。由严重急性呼吸综合征冠状病毒 2(SARS-CoV-2)引起的大流行需要最高覆盖率的疫苗。此外,病毒内部出现的突变对疫苗接种策略有重大影响。在这里,我们建立了一个全面的工作流程管道,以鉴定 SARS-CoV-2 病毒蛋白的 B 细胞和 T 细胞刺激抗原。我们的反向疫苗学(RV)方法包括两部分:(1)基于注释的细胞定位、抗原性、等位基因覆盖率、表位密度和突变密度对选定的病毒蛋白进行分析,(2)对表位的各个方面进行分析,包括抗原性、等位基因覆盖率、IFN-γ诱导、毒性、宿主同源性和突变密度。在对病毒变异中观察到的当代突变氨基酸取代进行突变分析后,选择了 13 个潜在的表位作为亚单位疫苗候选物。尽管发生了突变氨基酸取代,但大多数表位序列预计仍具有免疫原性而无毒性和宿主同源性。我们使用流水线的 RV 方法可能有助于缩短有效疫苗开发所需的时间,并且也可适用于其他致病性疾病的疫苗开发。